In heterozygous GDNF knockout mice the response of striatal dopaminergic system to acute morphine is altered

Synapse

Volumn 59, Issue 6, 2006, Pages 321-329

  Airavaara, Mikko ^a   Mijatovic, Jelena ^a   Vihavainen, Tanja ^a   Piepponen, Timo Petteri ^a   Saarma, Mart ^b   Ahtee, Liisa ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Dorsal striatum; Glial cell line derived neurotrophic factor; Hot plate; Microdialysis; Nucleus accumbens

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MORPHINE; TRANSCRIPTION FACTOR FOSB;

ALLELE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; GENOTYPE; KNOCKOUT MOUSE; MICRODIALYSIS; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN;

3,4-DIHYDROXYPHENYLACETIC ACID; ANALGESICS, OPIOID; ANIMALS; BINDING, COMPETITIVE; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; EXTRACELLULAR SPACE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HOMOVANILLIC ACID; MICE; MICE, KNOCKOUT; MICRODIALYSIS; MORPHINE; NARCOTICS; PAIN MEASUREMENT; REACTION TIME; STATISTICS, NONPARAMETRIC; TIME FACTORS; TRITIUM;

EID: 33645397888     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20245     Document Type: Article

References (46)

1. Ahtee L, Attila LM, Carlson KR, Haikala H. 1989. Changes in brain monoamine metabolism during withdrawal from chronic oral self-administration of morphine and in response to a morphine challenge in the withdrawn state. J Pharmacol Exp Ther 249:303-310.
2. Airaksinen MS, Saarma M. 2002. The GDNF family: signalling, biological functions and therapeutic value. Nature Rev Neurosci 3:383-394.
3. Airavaara M, Planken A, Gaddnas H, Piepponen TP, Saarma M, Ahtee L. 2004. Increased extracellular dopamine concentrations and FosB/ΔFosB expression in striatal brain areas of heterozygous GDNF knockout mice. Eur J Neurosci 20:2336-2344.
4. Altier N, Stewart J. 1998. Dopamine receptor antagonists in the nucleus accumbens attenuate analgesia induced by ventral tegmental area substance P or morphine and by nucleus accumbens amphetamine. J Pharmacol Exp Ther 285:208-215.
5. Attila LM, Ahtee L. 1984. Retardation of cerebral dopamine turn-over after morphine withdrawal and its enhanced acceleration by acute morphine administration in rats. Naunyn Schmiedebergs Arch Pharmacol 327:201-207.
6. Beck KD, Valverde J, Alexi T, Poulsen K, Moffat B, Vandlen RA, Rosenthal A, Hefti F. 1995. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 373:339-341.
7. Di Chiara G, Imperato A. 1986. Preferential stimulation of dopamine release in the nucleus accumbens by opiates, alcohol, and barbiturates: studies with transcerebral dialysis in freely moving rats. Ann N Y Acad Sci 473:367-381.
8. Di Chiara G, Imperato A. 1988. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274-5278.
9. Floresco SB, West AR, Ash B, Moore H, Grace AA. 2003. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci 6:968-973.
10. Franklin KBJ, Paxinos G. (1997). The Mouse Brain in Stereotaxic Coordinates, San Diego: Academic Press.
11. Gash DM, Zhang Z, Cass WA, Ovadia A, Simmerman L, Martin D, Russell D, Collins F, Hoffer BJ, Gerhardt GA. 1995. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J Comp Neurol 363:345-358.
12. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F, Hoffer BJ, Gerhardt GA. 1996. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380:252-255.
13. Gerhardt GA, Cass WA, Hudson J, Henson M, Zhang Z, Ovadia A, Hoffer BJ, Gash DM. 1996. In vivo electrochemical studies of dopamine overflow and clearance in the striatum of normal and MPTP-treated rhesus monkeys. J Neurochem 66:579-588.
14. Green-Sadan T, Kinor N, Roth-Deri I, Geffen-Aricha R, Schindler CJ, Yadid G. 2003. Transplantation of glial cell line-derived neurotrophic factor-expressing cells into the striatum and nucleus accumbens attenuates acquisition of cocaine self-administration in rats. Eur J Neurosci 18:2093-2098.
15. Hebert MA, Gerhardt GA. 1997. Behavioral and neurochemical effects of intranigral administration of glial cell line-derived neurotrophic factor on aged Fischer 344 rats. J Pharmacol Exp Ther 282:760-768.
16. Hebert MA, Van Horne CG, Hoffer BJ, Gerhardt GA. 1996. Functional effects of GDNF in normal rat striatum: presynaptic studies using in vivo electrochemistry and microdialysis. J Pharmacol Exp Ther 279:1181-1190.
17. Hoffer BJ, Hoffman A, Bowenkamp K, Huettl P, Hudson J, Martin D, Lin LF, Gerhardt GA. 1994. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 182:107-111.
18. Hurd YL, Kehr J, Ungerstedt U. 1988. In vivo microdialysis as a technique to monitor drug transport: correlation of extracellular cocaine levels and dopamine overflow in the rat brain. J Neurochem 51:1314-1316.
19. Johnson SW, North RA. 1992. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12:483-488.
20. Kalivas PW, Stewart J. 1991. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Brain Res Rev 16:223-244.
21. Kankaanpaa A, Meririnne E, Ariniemi K, Seppala T. 2001. Oxalic acid stabilizes dopamine, serotonin, and their metabolites in automated liquid chromatography with electrochemical detection. J Chromatogr B, Biomed Sci Appl 753:413-419.
22. Kearns CM, Gash DM. 1995. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 672:104-111.
23. Kearns CM, Cass WA, Smoot K, Kryscio R, Gash DM. 1997. GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis. J Neurosci 17:7111-7118.
24. Koob GF. 1992. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13:177-184.
25. Lacey MG, Mercuri NB, North RA. 1989. Two cell types in rat substantia nigra zona compacta distinguished by membrane properties and the actions of dopamine and opioids. J Neurosci 9:1233-1241.
26. Leone P, Pocock D, Wise RA. 1991. Morphine-dopamine interaction: ventral tegmental morphine increases nucleus accumbens dopamine release. Pharmacol Biochem Behav 39:469-472.
27. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. 1993. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132.
28. Maisonneuve IM, Warner LM, Glick SD. 2001. Biphasic dose-related effects of morphine on dopamine release. Drug Alcohol Depend 65:55-63.
29. Mansour A, Burke S, Pavlic RJ, Akil H, Watson SJ. 1996. Immunohistochemical localization of the cloned kappa 1 receptor in the rat CNS and pituitary. Neuroscience 71:671-690.
30. Matthews RT, German DC. 1984. Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine. Neuroscience 11:617-625.
31. Messer CJ, Eisch AJ, Carlezon WA, Jr., Whisler K, Shen L, Wolf DH, Westphal H, Collins F, Russell DS, Nestler EJ. 2000. Role for GDNF in biochemical and behavioral adaptations to drugs of abuse. Neuron 26:247-257.
32. Moore MW, Klein RD, Farinas I, Sauer H, Armanini M, Phillips H, Reichardt LF, Ryan AM, Carver-Moore K, Rosenthal A. 1996. Renal and neuronal abnormalities in mice lacking GDNF. Nature 382:76-79.
33. Nestler EJ, Barrot M, Self DW. 2001. ΔFosB: a sustained molecular switch for addiction. Proc Natl Acad Sci USA 98:11042-11046.
34. Pichel JG, Shen L, Sheng HZ, Granholm AC, Drago J, Grinberg A, Lee EJ, Huang SP, Saarma M, Hoffer BJ, Sariola H, Westphal H. 1996. Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 382:73-76.
35. Piepponen TP, Honkanen A, Kivastik T, Zharkovsky A, Turtia A, Mikkola JA, Ahtee L. 1999. Involvement of opioid mu1-receptors in opioid-induced acceleration of striatal and limbic dopaminergic transmission. Pharmacol Biochem Behav 63:245-252.
36. Pothos E, Rada P, Mark GP, Hoebel BG. 1991. Dopamine microdialysis in the nucleus accumbens during acute and chronic morphine, naloxone-precipitated withdrawal and clonidine treatment. Brain Res 566:348-350.
37. Rada P, Mark GP, Pothos E, Hoebel BG. 1991. Systemic morphine simultaneously decreases extracellular acetylcholine and increases dopamine in the nucleus accumbens of freely moving rats. Neuropharmacology 30:1133-1136.
38. Robinson TE, Berridge KC. 2003. Addiction. Annu Rev Psychol 54:25-53.
39. Sanchez MP, Silos-Santiago I, Frisen J, He B, Lira SA, Barbacid M. 1996. Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 382:70-73.
40. Sarabi A, Hoffer BJ, Olson L, Morales M. 2001. GFRalpha-1 mRNA in dopaminergic and nondopaminergic neurons in the substantia nigra and ventral tegmental area. J Comp Neurol 441:106-117.
41. Sauer H, Rosenblad C, Bjorklund A. 1995. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc Natl Acad Sci USA 92:8935-8939.
42. Segovia G, Del Arco A, Mora F. 1999. Effects of aging on the interaction between glutamate, dopamine, and GABA in striatum and nucleus accumbens of the awake rat. J Neurochem 73:2063-2072.
43. Smith JA, Loughlin SE, Leslie FM. 1992. Kappa-Opioid inhibition of [3H] dopamine release from rat ventral mesencephalic dissociated cell cultures. Mol Pharmacol 42:575-583.
44. Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, Olson L. 1995. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373:335-339.
45. Tseng JL, Baetge EE, Zurn AD, Aebischer P. 1997. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine. J Neurosci 17:325-333.
46. Zarrindast MR, Nassiri-Rad S, Pazouki M. 1999. Effects of dopaminergic agents on antinociception in formalin test. Gen Pharmacol 32:517-522.